Cargando…
表皮生长因子酪氨酸激酶抑制剂一线治疗突变阳性晚期非小细胞肺癌的临床疗效预测因素分析
BACKGROUND AND OBJECTIVE: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have demonstrated some dramatic efficacy in advanced non-small-cell lung cancer (NSCLC) patients with activating EGFR mutation. However, progression-free survivals (PFS) among those patients who were tr...
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
中国肺癌杂志编辑部
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6397942/ https://www.ncbi.nlm.nih.gov/pubmed/30827326 http://dx.doi.org/10.3779/j.issn.1009-3419.2019.02.04 |
Ejemplares similares
-
表皮生长因子受体酪氨酸激酶抑制剂在晚期非小细胞肺癌一线治疗中的应用
Publicado: (2010) -
非小细胞肺癌脑转移患者接受一代表皮生长因子受体酪氨酸激酶抑制剂治疗的临床研究
Publicado: (2017) -
酪氨酸激酶抑制剂耐药机制及其治疗策略
Publicado: (2011) -
BCR-ABL激酶区突变在酪氨酸激酶抑制剂耐药慢性髓性白血病患者中的分布及其影响因素
Publicado: (2020) -
酪氨酸激酶抑制剂时代成人Ph染色体阳性急性淋巴细胞白血病的治疗进展
Publicado: (2020)